Last $3.91 USD
Change Today +0.04 / 1.03%
Volume 12.3K
TBIO On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

transgenomic inc (TBIO) Snapshot

Open
$3.94
Previous Close
$3.87
Day High
$3.98
Day Low
$3.90
52 Week High
10/23/13 - $7.44
52 Week Low
06/20/14 - $3.10
Market Cap
28.8M
Average Volume 10 Days
8.7K
EPS TTM
$-2.49
Shares Outstanding
7.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TRANSGENOMIC INC (TBIO)

Related News

No related news articles were found.

transgenomic inc (TBIO) Related Businessweek News

No Related Businessweek News Found

transgenomic inc (TBIO) Details

Transgenomic, Inc. operates as a biotechnology company that focuses advancing personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and clinical and research services in the United States, Italy, the United Kingdom, Germany, France, and internationally. It operates in two segments, Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. This segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies. It employs various genomic testing service technologies, including ICE COLD-PCR technology, a proprietary platform technology that enables detection of multiple unknown mutations from virtually any sample type, including tissue biopsies, blood, cell-free DNA, and circulating tumor cells. The Genetic Assays and Platforms segment offers the WAVE System, which has applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. The company sells its products through direct sales, support staff, dealers, and distributors to academic and medical institutions; and pharmaceutical, biotech, and commercial companies. Transgenomic, Inc. has a strategic collaboration agreement with PDI, Inc. The company was founded in 1997 and is headquartered in Omaha, Nebraska.

165 Employees
Last Reported Date: 03/27/14
Founded in 1997

transgenomic inc (TBIO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $87.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $275.0K
Compensation as of Fiscal Year 2013.

transgenomic inc (TBIO) Key Developments

Transgenomic Inc. Presents at Craig-Hallum Capital Group's 5th Annual Alpha Select Conference, Sep-18-2014 08:40 AM

Transgenomic Inc. Presents at Craig-Hallum Capital Group's 5th Annual Alpha Select Conference, Sep-18-2014 08:40 AM. Venue: Convene Midtown East, 730 3rd Avenue, 17th Floor, New York, New York, United States. Speakers: Mark P. Colonnese, Chief Financial Officer, Principal Accounting Officer and Executive Vice President.

Transgenomic Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Transgenomic Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company's net sales were $6.8 million compared with $7.3 million a year ago. The year-to-year decline is attributable to a $0.3 million decrease in the Genetic Assays and Platforms segment, due to fewer instrument sales, and a $0.2 million decrease in the Laboratory Services segment, resulting from lower sales of contract development services to pharmaceutical clients. Loss from operations was $3.96 million compared with $2.92 million a year ago. Loss before income taxes was $3.9 million compared with $2.9 million a year ago. Net loss available to common stockholders was $4.2 million or $0.57 per basic and diluted share compared with $3.0 million or $0.41 per basic and diluted share a year ago. Modified EBITDA loss was $3.2 million compared with $2.2 million a year ago. For the six months, the company's net sales were $13.0 million compared with $14.7 million a year ago. The decline includes an 11% decrease in the Laboratory Services segment, which resulted from lower sales of contract laboratory services and from a higher than usual level of sales in the first half of 2013 that resulted from working down a backlog of Nuclear Mitome tests from the previous year. Loss from operations was $7.5 million compared with $6.7 million a year ago. Loss before income taxes was $7.6 million compared with $6.4 million a year ago. Net loss available to common stockholders was $8.6 million or $1.17 per basic and diluted share compared with $6.8 million or $0.95 per basic and diluted share a year ago. Modified EBITDA loss was $5.9 million compared with $5.1 million a year ago.

Transgenomic Inc. to Report Q2, 2014 Results on Aug 06, 2014

Transgenomic Inc. announced that they will report Q2, 2014 results at 5:00 PM, US Eastern Standard Time on Aug 06, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TBIO:US $3.91 USD +0.04

TBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Illumina Inc $177.92 USD +0.92
Laboratory Corp of America Holdings $106.06 USD -0.06
QIAGEN NV €18.36 EUR +0.065
Quest Diagnostics Inc $63.06 USD +0.14
Sequenom Inc $3.25 USD -0.06
View Industry Companies
 

Industry Analysis

TBIO

Industry Average

Valuation TBIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.1x
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TRANSGENOMIC INC, please visit www.transgenomic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.